|
JP2011257407A
|
|
Method and composition for measuring biological active natriuretic peptide and enhancing the possibility of treatment
|
|
EP2156187A1
|
|
Methods and compositions for diagnosis and/or prognosis of ovarian cancer and lung cancer
|
|
WO2008060607A2
|
|
Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
|
|
EP2049902A2
|
|
Devices and methods for performing receptor binding assays using magnetic particles
|
|
US2009004755A1
|
|
Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
|
|
WO2007140188A2
|
|
Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases
|
|
EP2005168A2
|
|
Methods and compositions for the diagnosis of diseases of the aorta
|
|
EP1974213A2
|
|
High sensitivity secretagogin assays and their uses for diagnosis and/or prognosis
|
|
WO2007075931A2
|
|
Reactive heterocyclic derivatives and methods for their synthesis and use
|
|
WO2007117330A2
|
|
Latent protein c assays and their uses for diagnosis and/or prognosis in systemic inflammatory response syndromes
|
|
EP1931990A2
|
|
Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
|
|
EP1929295A2
|
|
Use of soluble flt-1 and its fragments in cardiovascular conditions
|
|
WO2006135781A2
|
|
Methods and compositions for the diagnosis of venous thromboembolic disease
|
|
US2006228748A1
|
|
Hybrid phthalocyanine derivatives and their uses
|
|
WO2006078813A2
|
|
Arginine analogs, and methods for their synthesis and use
|
|
EP1949103A2
|
|
Diagnostic markers of stroke and cerebral injury and methods of use thereof
|
|
EP1794588A2
|
|
Methods and compositions for measuring canine bnp and uses thereof
|
|
US2006105419A1
|
|
Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
|
|
CA2576195A1
|
|
Compositions and methods for phage display of polypeptides
|
|
IL169348D0
|
|
Markers for differential diagnosis and methods of use thereof
|
